Lixiu Zhu,Jiawen Yan,Guoqiang Xu,Qiaoli Wang,Tianrui Xu,Ruixue Cao,Chuanzheng Sun,Yan Xi,Wei Xiong. Prognostic value of the long noncoding RNA AFAP1-AS1 in cancers. Oncol Transl Med, 2023, 9: 133-146.
Prognostic value of the long noncoding RNA AFAP1-AS1 in cancers
Received:June 14, 2022  Revised:May 29, 2023
View Full Text  View/Add Comment  Download reader
KeyWord:long noncoding RNA (lncRNA); actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1); prognostic; meta-analysis
Author NameAffiliationE-mail
Lixiu Zhu Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China 861354211@qq.com 
Jiawen Yan Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Guoqiang Xu Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Qiaoli Wang Department of Radiotherapy, People''s Hospital of Yuxi City, The Sixth Affiliated Hospital of Kunming Medical University, Yunnan 653100, China  
Tianrui Xu Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Ruixue Cao Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Chuanzheng Sun Department of Head and Neck Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Yan Xi Department of Head and Neck Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Wei Xiong Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan 650000, China  
Hits: 1664
Download times: 2619
Abstract:
      Objective This meta-analysis explored whether the expression of actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) is related to the prognosis and clinicopathological features of patients with cancer. Methods PubMed, EMBASE, and Cochrane Library were systematically searched. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the prognostic value based on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Odds ratios (ORs) with 95% CIs were used to determine the relationships between AFAP1-AS1 and clinicopathological features, such as large tumor size (LTS), high tumor stage (HTS), poor histological grade (PHG), lymph node metastasis (LNM), and distant metastasis (DM). Results Thirty-five eligible articles and 3433 cases were analyzed. High AFAP1-AS1 expression, compared to low AFAP1-AS1 expression, correlated with significantly shorter OS (HR = 2.15, 95% CI = 1.97–2.34, P < 0.001), DFS (HR = 1.37, 95% CI = 1.19–1.57, P < 0.001), and PFS (HR = 1.97, 95% CI = 1.56–2.50, P < 0.001) in patients with cancer. In various cancers, elevated AFAP1-AS1 expression was significantly associated with LTS (OR = 2.76, 95% CI = 2.16–3.53, P < 0.001), HTS (OR = 2.23, 95% CI = 1.83–2.71, P < 0.001), and PHG (OR = 1.39, 95% CI = 1.08–1.79, P = 0.01) but not LNM (OR = 1.59, 95% CI = 0.88–2.85, P = 0.12) or DM (OR = 1.81, 95% CI = 0.90–3.66, P = 0.10). Conclusion High AFAP1-AS1 expression was associated with prognostic and clinicopathological features, suggesting that AFAP1-AS1 is a prognostic biomarker for human cancers.
Close